US Patent 8,147,852 (Candidiasis/Ointment) Claims & Scope Deep Dive

US Drug Patent 8,147,852 claims a topical treatment method for human candidiasis using an ointment that includes, in defined claim sets, miconazole nitrate plus specific excipients and optionally fragrance. The claim set is built to capture (i) a generic “compound of the formula” embodiment in broad claim 1, (ii) defined formulation variants, and (iii) a narrower “consists of” formulation that locks component lists.

What is the core claim scope?

Independent claim structure is method-based, not product-based:

Claim 1 (anchor scope)

“A method of treating a human suffering from candidiasis” by:

Topically administering an effective amount of a pharmaceutical composition
The pharmaceutical composition is an ointment
The ointment comprises a compound of the formula (formula text not reproduced in the user prompt)

Claim 1 is the broadest because it requires only:

topical administration
ointment dosage form
candidiasis in a human
presence of the “compound of the formula” (scope depends on what that formula covers in the specification/drawings)

Claim 11 (tightens to a specific “combination ointment” set)

Claim 11 recites a more concrete formulation list, explicitly limited to:

miconazole nitrate
zinc oxide
white petrolatum
trihydroxystearin

It still recites:

topical administration
effective amount
ointment
candidiasis treatment

Claim 15 (strongest lock: “consists of”)

Claim 15 states the pharmaceutical composition “consists of”:

miconazole nitrate
zinc oxide
white petrolatum
trihydroxystearin
and optionally a fragrance

“Consists of” narrows scope by excluding additional ingredients beyond the listed set (except fragrance, and only to the extent it is optional and otherwise not displacing the listed constituents).

How do the dependency layers work?

The claims build through three main “layers”:

Treatment route and disease state (claims 1, 11, 15): topical ointment to treat candidiasis.
Formulation composition (claims 2-7 for claim 1; claims 11 for the full list; claim 15 for the locked list).
Patient and causative species (claims 8-9, 12-13, 16-17): candidiasis caused by specified Candida spp including C. albicans.
Comorbidity (claims 10, 14, 18): patient also has diaper rash.

Below is a claim-by-claim functional map of added limitations.

Scope by claim: what each claim adds

A. Claim 1 and its dependent formulation options

Claim 1 requires only:

human candidiasis
topical ointment
“compound of the formula”

Claim 2 adds: miconazole nitrate
Claim 3 adds: 2,6-di-tert-butyl-4-methylphenol
Claim 4 adds: zinc oxide
Claim 5 adds: petrolatum
Claim 6 narrows claim 5 to: white petrolatum
Claim 7 adds: trihydroxystearin

Net effect: claims 2-7 create a formulation “choice architecture” attached to claim 1. Any embodiment that matches the compound of the formula plus one or more of these add-ons can be within those dependent claim scopes depending on how the independent claim element is satisfied.

B. Claim 8-9: pathogen species

Claim 8 specifies the Candida species list:

C. albicans
C. tropicalis
C. glabrata
C. parapsiliosis
C. guilliermondi
C. lusitaniae
C. krusei

Claim 9 narrows to C. albicans.

Net effect: an asserted method can fall within these claims only when the disease is caused by a listed species. If the product treats candidiasis without specifying the species, claim coverage becomes a factual/diagnostic issue.

C. Claim 10: diaper rash comorbidity

Claim 10 narrows claim 1’s method to patients also suffering from diaper rash.

D. Claim 11-14: fixed composition set + optional comorbidity

Claim 11 requires a specific “combination” ointment:

miconazole nitrate
zinc oxide
white petrolatum
trihydroxystearin

Claim 12 adds the Candida species list (same seven-species set as claim 8).
Claim 13 narrows to C. albicans.
Claim 14 adds the comorbidity: diaper rash.

E. Claim 15-18: “consists of” formulation + same species and comorbidity

Claim 15 requires “consists of”:

miconazole nitrate
zinc oxide
white petrolatum
trihydroxystearin
optionally fragrance

Claim 16 adds the Candida species list. The list in your prompt includes a small transcription inconsistency (“Candida Candida Iusitaniae”) but the intended species is clearly Candida lusitaniae plus the other listed species.
Claim 17 narrows to C. albicans.
Claim 18 adds diaper rash.

Net effect: claim 15 is the most enforceable against competitors who use the same miconazole plus barrier/excipient package because it blocks additional formulation components via “consists of.”

What does the “compound of the formula” do to scope?

Claim 1’s language hinges on a compound of the formula without stating the chemical name in the user prompt. That element is the gatekeeper for the entire “claim 1 family” (claims 1-10).

In practice, the existence of dependent claims naming miconazole nitrate suggests the formula compound is likely to be miconazole-related or directly miconazole nitrate (or a salt/tautomeric equivalent described in the specification). But the independent claim is not limited to miconazole by its text, so coverage can extend to other formula embodiments.

Business impact:

A competitor formulation that uses zinc oxide + white petrolatum + trihydroxystearin but swaps out miconazole for a different antifungal may still land in claim 1 if the “compound of the formula” element is met.
A competitor that uses miconazole nitrate but uses different ointment bases or excipients may still miss claim 15 due to the “consists of” lock.

Enforcement-relevant claim boundaries

1) Composition boundary: “comprises” vs “consists of”

Claims 1 and 2-14 use “comprises” language (as shown by claim 1 and the inclusion-based dependent recitations). This tends to be broader: accused compositions may include extra ingredients and still infringe.
Claim 15 uses “consists of.” This is narrower and more defensible for the patentee:
- accused ointments that include other actives or different base components risk noninfringement on the ingredient-list limitation (unless the additional ingredient is a non-substantial impurity that does not contradict the “consists of” construction).

2) Disease definition boundary: Candida species

Claims 8-9, 12-13, and 16-17 add a causation element: “Candida spp selected from…”
That is a litigable factual requirement:

If the claimed method is pursued only on clinically-diagnosed “candidiasis” without species determination, enforcement may be constrained.
If clinical indications include common species (especially C. albicans), that subgroup supports tighter read across (claims 9, 13, 17).

3) Comorbidity boundary: diaper rash

Claims 10, 14, and 18 require diaper rash co-occurrence.

This narrows the target population and can drive product-positioning arguments: a product marketed for general cutaneous candidiasis versus diaper-area yeast may fall outside these specific dependent scopes.

Claim-to-product design map (where competitors get in trouble)

Below is a practical coverage matrix derived strictly from the claim text you provided.

Scenario A: “miconazole + zinc oxide + white petrolatum + trihydroxystearin”

High risk: matches claim 11 (comprises) and claim 15 (consists of) if no extra ingredients are used beyond optional fragrance.
Species and diaper rash terms then determine whether dependent claims 12-14 or 16-18 are implicated.

Scenario B: “miconazole + zinc oxide + petrolatum (not specified as white) + trihydroxystearin”

Claim 6 requires “white petrolatum” only in the claim 5 dependent path, but claim 11 explicitly requires white petrolatum.
Claim 1 dependent claim 5 is broader (“petrolatum”), but claim 11 still constrains to white petrolatum.
So variant petrolatum types increase design freedom relative to claim 11/15.

Scenario C: “miconazole + correct barrier/excipient package + added preservative (beyond those listed)”

Risks:
- Under “comprises” claims (1-14), additional ingredients can still infringe if other elements are met.
- Under “consists of” claim 15, additional ingredients beyond fragrance can break coverage.
Net: the main litigation lever is “consists of” tolerance for added non-fragrance ingredients.

Scenario D: “different antifungal but same ointment excipient base”

Potentially still hits claim 1 if the “compound of the formula” maps broadly enough in the specification to include the competitor’s active.
But if the competitor does not use the “compound of the formula” embodiment, claim 1 is not met.

What is the practical patent landscape for this patent?

From claims alone, the landscape is formulation-and-use specific

Your claim set is narrowly oriented around:

topical ointment delivery
candidiasis treatment of humans
specific miconazole nitrate + zinc oxide + white petrolatum + trihydroxystearin combination (claim 11)
tighter ingredient lock using “consists of” (claim 15)
optional use narrowing to Candida species and diaper rash

What the claim architecture typically means for the landscape:

Easy-to-copy actives exist (miconazole is old).
Risk shifts from “new active” to “new combination and formulation boundaries,” especially where “consists of” is present.
Competitors will often design around claim 15 by:
- substituting one base component, or
- adding a non-fragrance ingredient (if “consists of” is construed strictly), or
- using a different salt form or different active that does not map to the “compound of the formula” in claim 1.

Where the claims are most enforceable

Product claims are not present in what you shared; these are method claims.
Still, method claims can be enforced through:
- prescribing/dispensing practices
- labeling and promotional instructions that drive topical administration for candidiasis under the claimed conditions

The “diaper rash” dependent claims (10, 14, 18) are especially enforceable when products are positioned for diaper-area yeast and barrier protection.

Where enforcement is constrained

Species-limited dependents (8-9, 12-13, 16-17) require alignment with one of the listed Candida species.
If a competitor’s clinical and labeling strategy targets candidiasis without species specificity, they may attempt to avoid those narrower dependent claims, leaving only the broader claims where species limitation does not apply.

Breakdown of “design-around” options implied by the claim language

These are direct implications from the text you provided.

Avoid the “consists of” set in claim 15
- Any additional ingredient besides optional fragrance can create noninfringement exposure if construed strictly.
- Any substitution of one listed component (miconazole nitrate, zinc oxide, white petrolatum, trihydroxystearin) can also escape.
Use petrolatum not “white petrolatum”
- This can help avoid claim 11 and claim 15 where white petrolatum is required.
- However, claim 1 dependent paths may still capture if the formulation meets “petrolatum” language via claims 5-7, depending on how the “compound of the formula” is satisfied.
Target candidiasis without diaper rash positioning
- This avoids dependents 10, 14, 18.
- It does not avoid claims where diaper rash is not required (1, 11, 15).
Avoid Candida-species-specific practice
- This reduces capture of dependents 8-9, 12-13, 16-17.
- It does not avoid independent claim scope, which in your excerpt does not require species identification.

Claim Chart Summary (condensed)

Claim	Method element	Composition requirement (ointment)	Candida limitation	Diaper rash limitation
1	Treat human candidiasis; topical; effective amount; ointment	“comprises a compound of the formula”	No	No
2	Same as 1	Further comprises miconazole nitrate	No	No
3	Same as 1	Further comprises 2,6-di-tert-butyl-4-methylphenol	No	No
4	Same as 1	Further comprises zinc oxide	No	No
5	Same as 1	Further comprises petrolatum	No	No
6	Same as 5	Petrolatum is white petrolatum	No	No
7	Same as 1	Further comprises trihydroxystearin	No	No
8	Same as 1	(depends on claim 1 plus additional limits above if asserted with them)	Must be one of listed Candida spp	No
9	Same as 8	Candida is C. albicans	Yes	No
10	Same as 1	No extra composition beyond claim 1	No	Yes
11	Same method framing	comprises miconazole nitrate + zinc oxide + white petrolatum + trihydroxystearin	No	No
12	Claim 11	Same composition as 11	One of listed Candida spp	No
13	Claim 12	Candida is C. albicans	Yes	No
14	Claim 11	Same composition as 11	No	Yes
15	Same method framing	consists of miconazole nitrate + zinc oxide + white petrolatum + trihydroxystearin (+ optional fragrance)	No	No
16	Claim 15	Same composition as 15	One of listed Candida spp	No
17	Claim 16	Candida is C. albicans	Yes	No
18	Claim 15	Same composition as 15	No	Yes

Key Takeaways

US 8,147,852 is a topical method patent aimed at treating human candidiasis using an ointment.
The claim set splits into two enforceability tiers:
- claim 1 family: broad “compound of the formula” plus optional excipients (miconazole nitrate, zinc oxide, white petrolatum, trihydroxystearin, etc.).
- claims 11 and 15: fixed “miconazole + barrier excipient” combinations, with claim 15’s “consists of” being the sharpest design-around boundary.
Candida species dependents (claims 8-9, 12-13, 16-17) and diaper rash dependents (claims 10, 14, 18) narrow coverage based on causation and patient condition.
From a competitor standpoint, the highest-friction area is replicating the exact excipient package and ingredient permissiveness under claim 15.

FAQs

1) What is the single most important claim for formulation design?

Claim 15 is the main formulation lock because it uses “consists of” for: miconazole nitrate, zinc oxide, white petrolatum, trihydroxystearin, with only optional fragrance allowed.

2) Does the patent require identification of the Candida species?

Only for the dependent claims that recite specific Candida spp (claims 8-9, 12-13, 16-17). The independent treatment frameworks (claims 1, 11, 15) in your excerpt do not require species identification.

3) Does diaper rash matter to infringement?

Only for the dependent claims that explicitly add diaper rash: claims 10, 14, 18.

4) Can a product with additional ingredients still infringe this patent?

It depends on which claim is asserted. Claims using “comprises” (most of the set you provided) are more tolerant of extra components, while claim 15 using “consists of” is less tolerant.

5) What formulation combination is repeatedly targeted?

Across claims 11 and 15, the repeated combination is miconazole nitrate + zinc oxide + white petrolatum + trihydroxystearin.

References

[1] US Patent 8,147,852.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Mylan	VUSION	miconazole nitrate; white petrolatum; zinc oxide	OINTMENT;TOPICAL	021026-001	Feb 16, 2006		RX	Yes	Yes	8,147,852	⤷ Start Trial				USE FOR TREATMENT OF DIAPER DERMATITIS COMPLICATED BY CANDIDIASIS	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
World Intellectual Property Organization (WIPO)	2008019030	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Summary for Patent: 8,147,852